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Abstract: Treatment of brain metastases are controversial, being the optimal therapeutic combination still unknown. The 
aim of the present work was to determine the outcome differences among Whole Brain Radiation Therapy, Stereotactic 
Radiosurgery and Surgical Resection in terms of Overall Survival, Functional Independence, Local Control, Neurological 
Death and Neurocognitive Impairment. A systematically review of the pertinent literature was performed by using the 
Cochrane Register of Controlled Trials (CENTRAL/CCTR), MEDLINE, EMBASE, CINAHL and the ISRCTNR 
(International Standard Randomised Controlled Trial Number Register) databases. A total amount of 971 articles were 
encountered, including 19 Randomized Clinical Trials. High bias risk studies were excluded based on the Cochrane Bias 
Risk Tool and 14 RCT with low bias risk were selected. The combination of surgical resection and Whole Brain Radiation 
Therapy resulted in longer overall survival than Whole Brain Radiation Therapy alone. The combination of Whole Brain 
Radiation Therapy and Stereotactic Radiosurgery resulted in better Local Control and Overall Survival than Whole Brain 
Radiation Therapy alone. Significative differences were not found in terms of Local Control and Overall Survive between 
the combination of Whole Brain Radiation Therapy plus Stereotactic Radiosurgery and Stereotactic Radiosurgery alone 
but Neurocognition was less affected in patients treated with Stereotactic Radiosurgery. Current studies that compare 
different therapeutic modalities for 1 to 4 brain metastases are not conclusive. The best treatment for patients with 1-4 
brain metastases remains controversial. 
Keywords: Brain metastasis, Multimodal treatment, Radiosurgery, Whole brain radiation therapy, Surgical 
resection. 
INTRODUCTION 
The incidence of brain metastases (BM) in patients 
with cancer account for 10 to 40 % in the course of 
their illness [9], although some authors report this 
number higher than 40 % [19, 20]. Such disease 
represents the most frequent Central Nervous System 
lesion, being its incidence ten times higher than 
primary brain tumours [9] Furthermore, this pathology 
carries a poor prognosis for most of the patients [19]. 
About 170,000 new cases with BM are diagnosed 
every year in the United States [15]. The incidence of 
this pathology has increased during the last 40 years 2 
to 5 times despite recent scientific advances. Various 
factors seem to be responsible for such an 
increasement: the development of new diagnostic 
modalities, the increasing of survival rate for cancer 
patients and the diffusion of some chemotherapy 
agents, able to weak the blood-brain barrier. The most 
frequent primary tumour localization is the lung, 40 to 
50%, followed in order by breast, melanoma, renal, 
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Metastases can be single or multiple, where the 
multiples represent approximately 50% of all cases. 
With the term oligometastases are generally 
considered patients harbouring 1 up to 4 BM [16]. 
As for the majority of patients with a cancer, the 
treatment of oligometastases is palliative and 
multimodal, addressing to reduce the symptoms, to 
improve the Local Control (LC), Survival with 
Functional Independence (SFI), and Overall Survival 
(OS).  
Actually, conventional treatment modalities such 
Whole Brain Radiation Therapy (WBRT), Stereotactic 
Radiosurgery (SRS) and Surgical Resection (SR) have 
reached new levels of refinement. However, these 
achievements are somewhat muted by the emergence 
of Magnetic Resonance (MR)-guided laser interstitial 
thermal therapy or MR-guided focused ultrasound 
surgery, a minimally invasive neuroablative techniques 
[16, 23]. 
WBRT is used to treat noted metastases or as a 
prophylactic cranial irradiation against micrometastases 
not detected by neuroradiologic investigations. WBRT 
constitutes the standard palliative treatment for 
oligometastases and increases up to 3 times the OS 
average when compared with steroid treatment alone 
6    World Journal of Oncology Research, 2015, Vol. 2 García et al. 
(OS from 3 up to 9 month) [5]. Best results are 
obtained in patients younger than 60 years, with a 
Karnofsky Performance Status (KPS) score of 70 or 
higher, a radiosensitive primary tumor and controlled 
primary disease. The optimal dose remains uncertain 
and delivery schemes have changed widely in the 
literature [10]. 
The SRS is an interdisciplinary procedure that 
requires the use of high resolution anatomical images, 
specialized instrumentation and rigid immobilization. It 
combines stereotactic principles with high intensity 
focal radiation. High ionizing radiation doses are 
delivered to the target through beams generated with a 
Linear Accelerator (LINAC) or Cobalto multisource 
devices (Gamma Knife) while sparing normal tissue. 
The total dose is normally applied in one session, 
although is possible to apply up to five sessions [23]. 
SRS is frequently used for initial handling or adjuvant 
therapy after SR or WBRT [22]. It has been reported as 
having successful LC rates up to 70-80% of patients 
[4]. 
Focal treatment of oligometastases with SR has 
shown an improvement in tumor LC and extension of 
OS, especially when combined with WBRT. Indications 
for SR as primary therapeutical modality include one or 
some of the following circumstances: unknown primary 
tumour; significant mass effect including edema that 
requires rapid relieve; symptomatic lesions, localized in 
no eloquent areas, and surgically accessible (not deep 
situation) [17]. However, SR can be contraindicated in 
many patients due to co morbid associated conditions 
or non resectable lesion. Potential benefits of SR must 
be counterbalanced with morbidity risks and after 
surgical mortality. 
WBRT utilization is also controversial because of 
the potential neurocognitive damage that it produces 
[23]. 
Taking into account these elements, we made the 
following question: what is the therapeutic modality that 
offers the best results attending to OS, SFI, LC, 
Neurological Death (ND) and Neurocognition? 
METHODS 
It was made a qualitative systematic review 
retrospective study.  
Study Selection Criteria 
Randomized Control Trials (RCT) that compare SR, 
SRS and WBRT alone or in combination, in patients 
older than 18 years with oligometastases, histologically 
confirmed, regardless primary tumor localization were 
selected. 
Study Exclusion Criteria 
RCT in patients with no controlled primary tumor, as 
well as those without a Computed Tomography (CT) or 
a Magnetic Resonance Image (RMI) diagnosis, mainly 
before the 1980´s. High bias risk studies were 
excluded. 
Therapeutic Modalities 
The considered therapeutic modalities were: 
• SRS with rigid frame or mask, in single or 
repeated fractions, with LINAC or Gamma Knife 
• SR 
• WBRT alone or associated to another modality 
Variables 
Primary Variable 
OS, as defined from the time of patient inclusion in 
the study 
Secondary Variable 
1-SFI: The time that the patient remained with a 
KPS equal to or higher than 70 or with a rating lower 
than or equal to 1 according to the World Health 
Organization (WHO) scales. 
2-LC: Lesion recurrence rate 
3-Neurocognitive damage as measured by the 
Hopkins Verbal Learning Test (HVLT) [3]. 
4-ND: Death rate due to brain disease progression. 
Search Strategies and Studies´ Selection 
The search was made in the following electronic 
databases: Cochrane Register of Controlled Trials 
(CENTRAL/CCTR), MEDLINE, EMBASE, CINAHL and 
the ISRCTNR (International Standard Randomised 
Controlled Trial Number Register). 
The following terms were used, in english as well as 
spanish.  
In english: solitary/ single/oligo-brain/cerebral 
metastasis/metastases, surgery/ neurosurgery/micro- 
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surgery, radiosurgery/stereotactic radiosurgery, whole 
brain radiotherapy/radiation therapy/ irradiation and 
randomised/controlled trial/ Gamma knife/ recursive 
partitioning analysis.  
In spanish: enfermedad metastásica cerebral/ 
metástasis cerebral/ cirugía/ radiocrugía/ radioterapia 
holocraneal/ reirradiación/ radionecrosis/ análisis de 
particionamiento recursivo/ bisturí de rayos gamma/ 
escalación de dosis/ lesiones radioresistentes/ 
oligometastasis/ factores pronósticos. 
The references lists of the identified studies were 
also checked to search additional studies. There was 
not language limitation. 
REVIEW METHODS 
Bias Risk in the selected studies was based on the 
Cochrane Bias Risk Tool [6]. 
The following exclusion criteria were considered: 
1-Improper randomization 
2-Lack of blinding methodologies for participants 
3-Incomplete data 
With respect to these criteria, studies were divided 
into 
1-Yes (low bias risk) 
2-No (high bias risk) 
3-Unknown (unknown bias risk) 
Only the “Yes” studies were accepted for our 
analysis. 
The treatment modalities were classified as follows: 
1-SR alone 
2-SR and WBRT 
3-SRS alone, including all techniques: Gamma 
Knife, LINAC, with rigid or recolocatable frame. 
4-SRS, all techniques, plus WBRT 
5-WBRT alone 
RESULTS 
The search initially found 971 published articles. 
Among them, there were 19 RCT. When the Cochrane 
Bias Risk Tool was applied, a sample of 14 RCT with 
low bias risk was selected (Table 1). 
SR PLUS WBRT VS WBRT 
In 1990, in a RCT with 48 patients (25 with SR plus 
WBRT and 23 with WBRT alone) in Kentucky, USA, 
Patchell et al. [13] founded an increase in OS (40 
weeks versus 15, p<0.01), better LC (20% recurrence 
versus 52%, p<0.02) and longer SFI, determined as 
the time that the patient retained a KPS equal or higher 
than 70 (38 weeks versus 8 weeks, p<0.005) with the 
combination of SR plus WBRT. 
In 1993, Vetch et al. [21] conducted a multicenter 
study with a sample of 66 patients. WBRT was 
delivered in 2 Gy sessions, twice a day, for 2 weeks. In 
this trial, OS was established since the randomization 
time. SFI was evaluated according to the WHO scale. 
Before randomization, patients were classified 
according to the primary tumor localization (lung versus 
not lung) and extracranial disease level (stable or 
progressive). Mean OS was 10 months in patients 
treated with SR plus WBRT and 6 months in those 
treated with WBRT alone (p<0.04). Results were 
similar in lung or not lung groups. For those cases with 
progressive primary disease, OS was low in both 
groups, with a mean value of 5 months. SFI was longer 
in the group that received combined treatment 
(p<0.06). The authors concluded that patients with 
stable primary disease and 1-4 brain metastases had 
tobe treated with SR and WBRT, while WBRT alone 
was acceptable for patients with progressive primary 
disease during the previous three months. 
In 1994, Noordjik et al. [11] published a similar 
study with 66 patients. SR and WBRT were similar to 
the Vetch´s study [21]. Combined treatment allowed a 
longer mean OS (12 months vs 7 months, p = 0.02). 
Patients with extracranial active disease had a mean 
OS of 5 months, independently of the therapeutic 
modality. As for the SFI, the achieved results were 
similar for both groups. 
In 1996, Mintz et al. [7] published another 
multicenter study with an 84 patient’s sample. WBRT 
was administered up to a total dose of 30 Gy, in 2 Gy 
daily sessions for 2 weeks. It was not found a 
significant improvement in any of the two groups. 36 
patients with the combination of WBRT and SR and 30 
patients with WBRT alone died in the course of the 
year, p=0.24. ND and SFI were similar in both groups. 
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SR PLUS WBRT VS SR  
In 1998, Patchell et al. [12] published a RCT with 95 
patient’s wit oligo brain metastases. They compared 
evolution of patients with SR plus WBRT 28 fractions, 
54 Gy each one vs SR alone. They found that addition 
of WBRT improved LC (10% recurrence rate vs 46%, 
p<0.001) and neurological death rate (14% vs 44%, p = 
0.003) but it did not influenced OS (mean values of 11 
months vs 10 months, p = 0.39) or SFI (KPS equal or 
higher than 70 during 8.5 vs 8 months, p = 0.61). 
Roos et al. in 2006 [18] , evaluated the effect of 
adjuvant WBRT after SR or SRS in 19 patients with 
solitary brain metastases, 17 patients had SR and one 
in each arm had SRS. They didn't observe significant 
differences in OS SFI but tendency was observed to 
reduce the ND. This RCT was suspended by the Trial 
Management Committee on 31 July 2000 due to slow 
accrual and closed on the recommendation of the 
Radiation Therapy Oncology Group (RTOG) Scientific 
Committee on 14 October 2000. 
SR PLUS WBRT VS SRS 
In a multicenter study reported by Muacevic et al. 
[8] with a sample of 70 patients, there were not 
significant differences found with respect to LC (p = 
0.08) and neurological death (p = 0.3). 
SR PLUS WBRT VS WBRT PLUS SRS 
There are no studies with low bias risk. 
WBRT PLUS SRS VS WBRT  
In 2004 a phase III RCT involving 331 patients with 
1 to 3 metastases was conducted by Andrews, Scot et 
al. [1] from RTOG. They compared the results in a 
phase III study including 331 patients with 1 to 3 
metastases. There was no difference in OS, neither in 
Table 1: Summary of the RCT Selected 
Authors and 
Year 
Arms OS LC SFI ND Neurocognition 
Patchell el al. 
1990 
SR plus WBRT 
(n = 25) versus 
WBRT (n = 23) 
9.2 months versus 
3.5 months (p < 
0.01) 
13.6 months 
versus 4.8 months 






Vetch et al. 
1993 
SR (n = 32) plus 
WBRT vs WBRT 
(n = 31) 
10 months versus 
6 months(p<0.04) 
NE NE NE NE 
Noordjik et al. 
1994 
SR plus WBRT vs 
WBRT (n = 66) 
12 months vs 7 
months, p = 0.02 
NE NE NE NE 
Mintz et al. 1996 
SR plus WBRT vs 
WBRT (n = 84) 
NE NE NE NE NE 
Patchell et al. 
1998 
SR plus WBRT vs 
SR (n = 95) 
11 months vs 10 
months, p = 0.39 
10% recurrence 
rate vs 46%, 
p<0.001 
KPS equal or 
higher than 70 
during 8.5 vs 8 
months, p = 0.61 
14% vs 
44%, p = 
0.003 
NE 
Andrews et al. 
2004 
SRS +WBRT 
(n = 164) versus 
WBRT (n = 167) 
5.7 months versus 
6.5 months (p= 
NS) 
82% versus 71% 
(p = 0.01) 





vs. Worse or 
unchanged: 48% 
Aoyama et al. 
2006 
SRS +WBRT  
(n = 65) SRS alone 
(n = 67) 
8.0 months 7.5 
months (P = NS) 
53.2% 
23.6% 





Muacevic et al. 
2008 
SR plus WBRT vs 
SRS (n = 70) 
9.5 months versus 
10.3 months  
(P = NS) 
82% versus 97% 
(P = NS) 
NE NE NE 
Chang et al. 
2009 
SRS (n = 30) vs 
WBRT  SRS  
(n = 28) 
63% vs 21%  
(p =.003) 
67% vs 100%  




decline at 4 
months: 24% vs 
52% 
*Abbreviations: OS: Overall Survival; SFI: Survival with Functional Independence; NE: Not evaluated; LC: Local Control; MMSE: Mini Mental Exam. ND: 
Neurological Death; NS: Not Specificate. 
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mental status between the 2 arms based on the Mini-
Mental Status Exam (MMSE). No patient experienced 
acute grade 3 or 4 toxicities in the WBRT alone arm, 
however, 2% grade 3 and 1% grade 4 acute toxicities 
were observed in those treated with WBRT and SRS. 
Patil and Pricola et al. [14] compared the results 
between WBRT and WBRT plus SRS in single and 
multiple metastases. They concluded that SRS plus 
WBRT showed no benefits over WBRT. However, SRS 
plus WBRT improved the SFI and LC. 
WBRT PLUS SRS VS SRS 
Roos et al. [18], in 2006 compared 19 patients that 
received WBRT with 30 to 36 Gy doses supplemented 
with SRS, with 9 patients that received SRS alone. 
Even though differences between both arms were not 
found, this RCT was abandoned without conclusions.  
Aoyama et al. [2], in a RCT with a sample of 128 
patients, did not find statistically significant differences 
concerning OS. Nevertheless, in a more recent RCT 
carried out by Chang et al. [3], in 2009, enrolling 58 
patients with 1 to 3 metastases treated with SRS plus 
WBRT (30 Gy in 10 fractions) versus SRS, the SRS 
arm increased the OS. 
Chang et al. [3] assessed Neurocognition using 
HVLTRevised. Patients who received WBRT (30 Gy 
in 12 fractions) plus SRS showed a significant decline 
in learning and memory function compared with the 
group that received SRS alone. 
SR VS SRS  
There are no studies with low bias risk. 
DISCUSSION 
SR Plus WBRT Vs WBRT 
The results of the studies that compare SR plus 
WBRT with WBRT were not consistent due to several 
reasons. Samples sizes were smaller (48, 63, 66, 84, 
respectively). There were significant differences among 
the volume baseline information. All the patients from 
the Patchel study were diagnosed through Magnetic 
Resonance Imaging (MRI) [12]. In Noordijk's study MRI 
was optional and no biopsy was obtained [11]. Mintz 
patients were confirmed by Computerized Axial 
Tomography (CT) and biopsy was obtained only when 
diagnosis was not clear [7]. 
The studies showed different ratios of number of 
patients regarding both arms. Studies exhibited 
different eligibility criterion: Mintz et al. [7], selected 
patients with a scale of performance status of KPS of 
50 or higher, Patchell et al. [12] selected patients with 
KPS of 70 or higher while Noordijk et al. [11] selected 
patients using the scale of World Health Organization 
(WHO) equal 1 or lower. In addition, they studied 
different ratios of patients with extracranial tumors. 
None of them assess the LC.  
It is remarkable that in 3 of 4 studies, longer OS 
were observed in the SR plus WBRT arm. 
These results could be related with the decrease of 
the neurological death. 
According with Chang analysis [3], the OS is 
determined by powerful prognostic factor such as: 
primary tumor type, systemic stage of the disease, and 
the systemic chemotherapy effect. 
SR Plus WBRT Vs SR 
Only one comparative RT between SR plus WBRT 
and SR showed benefits related to combination over 
the SR, concerning the LC and neurological death, with 
no differences regarding OS. SRS could show the 
same results as SR but with less morbidity because 
complications during and after the SR are lower. In 
addition, SRS offers more comfort to the patient 
requiring a shorter hospital stay, with lower costs.  
SR Plus WBRT Vs SRS 
Only one comparative RCT between SR plus WBRT 
and SRS was found [8]. The results exhibit no 
statistically significant differences between both 
modalities. However this study had some limitations: it 
was prematurely abandoned. 
WBRT Plus SRS Vs WBRT 
Only two comparative RCT, performed by RTOG, 
between these modalities was found [1, 14]. An 
advantage was reported favouring patients treated with 
WBRT plus SRS regarding LC. 
These results showed that LC variable depends on 
the dose. LC increases when radiobiological dose 
increase, like in SRS-WBRT combination. According 
with these evidences we could assume that increasing 
the SRS dose we can obtain the same LC as in SRS-
WBRT combination. OS was statistically significant 
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higher in patients with good prognostic (less than 65 
years old, KPS > = 70, and stable primary tumour, 
without extracraneal metastases) treated with the SRS-
WBRT combination than in patients with a poor 
prognostic.  
WBRT Plus SRS vs SRS 
Three RCT, which compare these combinations, 
were found [2, 3, 18]. 
The Aoyama group assessed the neurocognitive 
functions through the Mini-Mental Status Exam 
(MMSE) without detecting differences between the two 
arms [2]. However these results are questionable since 
MMSE is not a useful tool to evaluate neurocognitive 
damages. Although WBRT improved the LC, Aoyama 
et al. [2]
 
and Patil et al.
 
[14] concluded that SRS alone 
should be considered as a routine treatment due to the 
low neurocognitive damage, low risk of adverse effects 
and does not affect the SFI. These evidences favored 
the usage of SRS.  
As conclusion, the addition of SRS to the WBRT 
improved a litter bit the OS, LC, and the Quality of life 
with regard to WBRT alone. Some physicians defend 
the usage of SRS alone since adding WBRT to SRS 
provokes a deterioration of the neurocognitive function 
and there are not benefits in the OS with respect to the 
SRS alone, therefore they prefer to apply repeated 
SRS or subsequent WBRT in case of progression of 
the disease [10]. 
Some authors affirm that LC failure with WBRT 
alone affect the neurocognitive function more than the 
WBRT effects [3, 19]. Although the authors of the 
present study think that WBRT are effective to avoid 
new lesions but, in spite of that, it has less 
effectiveness in LC than SRS so we can obtain less 
neurocognitive damage without WBRT. 
It has to be taken into account that SRS could be 
repeated in the time, (repeated SRS) avoiding the 
cerebral damage caused by WBRT. However, while 
SRS is performed in one session, WBRT requires 
several sessions.  
On the other hand, histology should be always 
considered before to choose any treatment. In fact, 
several types of lesions have higher frequency of 
relapse, or are radioresistant, being WBRT not useful. 
The comparison between WBRT added to SRS and 
SRS or SR alone in patients with few BM and 
controlled primary tumor, remain controversial. National 
Comprehensive Cancer Network (NCCN) guides [9] 
suggest three different therapeutic options to patients 
with 1-3 resectable metastases and limited systemic 
disease:  
1- SR plus WBRT 
2- SRS plus WBRT 
3- SRS. 
WBRT, SRS or both can be used in case of non 
resectable lesions. There is no general consensus 
within the American College of Radiology about the 
therapeutic recommendation to single brain metastases 
mainly because of the adverse effect of WBRT on the 
neurocognitive function. 
We have to highlight that HVLTR is the most 
frequently used test to evaluate neurocognitive 
damages in patients with brain metastases, although it 
mainly measures the memory functions missing others 
neurocognitive functions. 
We consider that neurocognitive functions should 
be measured with a more comprehensive group of 
tests since the commonly used tests prove to be 
incomplete. 
CONCLUSION 
This retrospective study compares different 
therapeutic modalities for 1 to 4 brain metastases 
treatment. However, the optimal treatment is not well 
defined yet and remains a controversial topic. Further 
researches should assesssome controversial variables 
we highlighted in order to increase the quality of clinical 
evidence.  
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